Wani Javaid Ahmad, Majid Sabhiya, Imtiyaz Zuha, Rehman Muneeb U, Alsaffar Rana M, Shah Naveed Nazir, Alshehri Sultan, Ghoneim Mohammed M, Imam Syed Sarim
Department of Biochemistry, Government Medical College (GMC-Srinagar), Karan Nagar, Srinagar 190010, J&K, India.
Clinical Drug Development of Herbal Medicine, College of Pharmacy, Taipei Medical University, Taipei 11031, Taiwan.
Diagnostics (Basel). 2022 Jul 1;12(7):1610. doi: 10.3390/diagnostics12071610.
Lung cancer is the dominant emerging factor in cancer-related mortality around the globe. Therapeutic interventions for lung cancer are not up to par, mainly due to reoccurrence/relapse, chemoresistance, and late diagnosis. People are currently interested in miRNAs, which are small double-stranded (20-24 ribonucleotides) structures that regulate molecular targets (tumor suppressors, oncogenes) involved in tumorigeneses such as cell proliferation, apoptosis, metastasis, and angiogenesis via post-transcriptional regulation of mRNA. Many studies suggest the emerging role of miRNAs in lung cancer diagnostics, prognostics, and therapeutics. Therefore, it is necessary to intensely explore the miRNOME expression of lung tumors and the development of anti-cancer strategies. The current review focuses on the therapeutic, diagnostic, and prognostic potential of numerous miRNAs in lung cancer.
肺癌是全球癌症相关死亡中占主导地位的新兴因素。肺癌的治疗干预措施尚不完善,主要原因是复发/再发、化疗耐药和诊断延迟。目前人们对微小RNA(miRNA)很感兴趣,它们是小的双链(20 - 24个核糖核苷酸)结构,通过对mRNA的转录后调控来调节参与肿瘤发生(如细胞增殖、凋亡、转移和血管生成)的分子靶点(肿瘤抑制因子、癌基因)。许多研究表明miRNA在肺癌诊断、预后和治疗中发挥着越来越重要的作用。因此,有必要深入探索肺肿瘤的miRNome表达以及抗癌策略的发展。本综述重点关注众多miRNA在肺癌治疗、诊断和预后方面的潜力。